Philip P. Connell
YOU?
Author Swipe
View article: Supplementary Figure 1 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Supplementary Figure 1 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma Open
MYCN/MYC expression in N-type and S-type neuroblastoma cell lines
View article: Supplementary Figure 2 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Supplementary Figure 2 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma Open
MELK and EZH2 RNA expression
View article: Data from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Data from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma Open
Maternal embryonic leucine zipper kinase (MELK) activates pathways that mediate aggressive tumor growth and therapy resistance in many types of adult cancers. Pharmacologic and genomic inhibition of MELK impairs tumor growth and increases …
View article: Supplementary Figure 1 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Supplementary Figure 1 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma Open
MYCN/MYC expression in N-type and S-type neuroblastoma cell lines
View article: Supplementary Figure 2 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Supplementary Figure 2 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma Open
MELK and EZH2 RNA expression
View article: Supplementary Figure 3 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Supplementary Figure 3 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma Open
pRPA32 expression in neuroblastoma cells treated with OTS167 and CPT.
View article: Supplementary Figure 3 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Supplementary Figure 3 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma Open
pRPA32 expression in neuroblastoma cells treated with OTS167 and CPT.
View article: Data from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Data from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma Open
Maternal embryonic leucine zipper kinase (MELK) activates pathways that mediate aggressive tumor growth and therapy resistance in many types of adult cancers. Pharmacologic and genomic inhibition of MELK impairs tumor growth and increases …
View article: Supplementary Legends and Figures from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer
Supplementary Legends and Figures from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer Open
This file includes: (1) legends for Supplementary Figures S1-S8 and Tables S1-S5 and (2) Supplementary Figures S1-S8. Figure S1: Study flow chart for selection of breast cancer patients. Figure S2: Distributions of SCAN normalized gene exp…
View article: Supplementary Tables from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer
Supplementary Tables from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer Open
This file includes Supplementary Tables S1-S5. Table S1: Eligible neoadjuvant chemotherapy breast cancer datasets. Table S2: Reference breast cancer datasets for gene expression normalization. Table S3: List of duplicate samples excluded f…
View article: Supplementary Tables from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer
Supplementary Tables from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer Open
This file includes Supplementary Tables S1-S5. Table S1: Eligible neoadjuvant chemotherapy breast cancer datasets. Table S2: Reference breast cancer datasets for gene expression normalization. Table S3: List of duplicate samples excluded f…
View article: Supplementary Legends and Figures from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer
Supplementary Legends and Figures from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer Open
This file includes: (1) legends for Supplementary Figures S1-S8 and Tables S1-S5 and (2) Supplementary Figures S1-S8. Figure S1: Study flow chart for selection of breast cancer patients. Figure S2: Distributions of SCAN normalized gene exp…
View article: Data from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer
Data from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer Open
Purpose: Molecular-based cancer tests have been developed to augment the standard clinical and pathologic features used to tailor treatments to individual breast cancer patients. Homologous recombination (HR) repairs double-stranded…
View article: Data from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer
Data from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer Open
Purpose: Molecular-based cancer tests have been developed to augment the standard clinical and pathologic features used to tailor treatments to individual breast cancer patients. Homologous recombination (HR) repairs double-stranded…
View article: Data from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
Data from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors Open
RAD51 is the central protein that catalyzes DNA repair via homologous recombination, a process that ensures genomic stability. RAD51 protein is commonly expressed at high levels in cancer cells relative to their noncancerous precursors. Hi…
View article: Supplementary Materials, Figures 1 - 2, Table 1 from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
Supplementary Materials, Figures 1 - 2, Table 1 from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors Open
PDF file - 403KB, Supplemental Figure 1. Quantifications of western blots. Supplemental Figure 2. Knockdown of RAD51 in PC3 does not protect cells from the toxicity of ionizing radiation. Supplemental Table 1. Quantifications of statistica…
View article: Supplementary Materials, Figures 1 - 2, Table 1 from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
Supplementary Materials, Figures 1 - 2, Table 1 from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors Open
PDF file - 403KB, Supplemental Figure 1. Quantifications of western blots. Supplemental Figure 2. Knockdown of RAD51 in PC3 does not protect cells from the toxicity of ionizing radiation. Supplemental Table 1. Quantifications of statistica…
View article: Data from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
Data from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors Open
RAD51 is the central protein that catalyzes DNA repair via homologous recombination, a process that ensures genomic stability. RAD51 protein is commonly expressed at high levels in cancer cells relative to their noncancerous precursors. Hi…
View article: <i>STK11</i>Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer
<i>STK11</i>Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer Open
PURPOSE Molecular factors predicting relapse in early-stage non–small-cell lung cancer (ES-NSCLC) are poorly understood, especially in inoperable patients receiving radiotherapy (RT). In this study, we compared the genomic profiles of inop…
View article: A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy
A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy Open
Personalized treatment approaches for patients with limited liver metastases from colorectal cancer are critically needed. By leveraging three large, independent cohorts of patients with colorectal liver metastases ( n = 336), we found tha…
View article: Noncanonical NF-κB factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy
Noncanonical NF-κB factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy Open
Homologous recombination (HR) serves multiple roles in DNA repair that are essential for maintaining genomic stability, including double-strand DNA break (DSB) repair. The central HR protein, RAD51, is frequently overexpressed in human mal…
View article: Mechanisms of distinctive mismatch tolerance between Rad51 and Dmc1 in homologous recombination
Mechanisms of distinctive mismatch tolerance between Rad51 and Dmc1 in homologous recombination Open
Homologous recombination (HR) is a primary DNA double-strand breaks (DSBs) repair mechanism. The recombinases Rad51 and Dmc1 are highly conserved in the RecA family; Rad51 is mainly responsible for DNA repair in somatic cells during mitosi…
View article: An Analysis of Patient Characteristics and Clinical Outcomes in Primary Pulmonary Sarcoma
An Analysis of Patient Characteristics and Clinical Outcomes in Primary Pulmonary Sarcoma Open
INTRODUCTION: Literature concerning primary pulmonary sarcomas (PPS) is limited to small case series. This study examines, in a large cohort, the clinical characteristics and therapeutic strategies of PPS and their impact on overall surviv…
View article: Targeting Non-Canonical NFκB2 to Determine the Effects on Radiation Sensitization
Targeting Non-Canonical NFκB2 to Determine the Effects on Radiation Sensitization Open
View article: CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer Open
View article: Chromosomal instability mediates immune exclusion and response to cytotoxic chemotherapy in colorectal liver metastases
Chromosomal instability mediates immune exclusion and response to cytotoxic chemotherapy in colorectal liver metastases Open
The genomic drivers of immune exclusion in colorectal cancer liver metastases (CRCLM) remain poorly understood. Chromosomal instability (CIN), resulting in aneuploidy and genomic rearrangements, is the central pathway of mismatch repair-pr…
View article: qRT-PCR-based DNA homologous recombination associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer
qRT-PCR-based DNA homologous recombination associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer Open
Purpose Cumulative evidences suggested the addition of platinum agents as neoadjuvant chemotherapy (NACT) could improve pathologic complete response (pCR) in triple-negative breast cancers (TNBC). We tried to develop a DNA homologous recom…
View article: QRT-PCR-based DNA Homologous Recombination Associated 4-Gene Score Predicts Pathologic Complete Response to Platinum-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
QRT-PCR-based DNA Homologous Recombination Associated 4-Gene Score Predicts Pathologic Complete Response to Platinum-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Open
BackgroundCumulative evidences suggested the addition of platinum agents as neoadjuvant chemotherapy (NACT) could improve pathologic complete response (pCR) in triple-negative breast cancers (TNBC). Previous studies showed DNA homologous r…
View article: P14.27 Pathogenic Genomic Alterations of CDKN2A Predict Immunotherapy Resistance in NSCLC
P14.27 Pathogenic Genomic Alterations of CDKN2A Predict Immunotherapy Resistance in NSCLC Open
View article: Targeting of Non-canonical NF-κB Factor p100/p52 Inhibits Homologous Recombination and Sensitizes Cancer Cells to DNA-damaging Therapy
Targeting of Non-canonical NF-κB Factor p100/p52 Inhibits Homologous Recombination and Sensitizes Cancer Cells to DNA-damaging Therapy Open